Your browser doesn't support javascript.
loading
The impact of the COVID-19 pandemic on cardiovascular disease prevention and management.
Dale, Caroline E; Takhar, Rohan; Carragher, Raymond; Katsoulis, Michail; Torabi, Fatemeh; Duffield, Stephen; Kent, Seamus; Mueller, Tanja; Kurdi, Amanj; Le Anh, Thu Nguyen; McTaggart, Stuart; Abbasizanjani, Hoda; Hollings, Sam; Scourfield, Andrew; Lyons, Ronan A; Griffiths, Rowena; Lyons, Jane; Davies, Gareth; Harris, Daniel; Handy, Alex; Mizani, Mehrdad A; Tomlinson, Christopher; Thygesen, Johan H; Ashworth, Mark; Denaxas, Spiros; Banerjee, Amitava; Sterne, Jonathan A C; Brown, Paul; Bullard, Ian; Priedon, Rouven; Mamas, Mamas A; Slee, Ann; Lorgelly, Paula; Pirmohamed, Munir; Khunti, Kamlesh; Morris, Andrew D; Sudlow, Cathie; Akbari, Ashley; Bennie, Marion; Sattar, Naveed; Sofat, Reecha.
Afiliação
  • Dale CE; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
  • Takhar R; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
  • Carragher R; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Katsoulis M; Centre for Public Health, Queen's University Belfast, Belfast, UK.
  • Torabi F; MRC Unit for Lifelong Health and Ageing, Institute of Cardiovascular Science, University College London, London, UK.
  • Duffield S; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, UK.
  • Kent S; National Institute for Health and Care Excellence, London, UK.
  • Mueller T; National Institute for Health and Care Excellence, London, UK.
  • Kurdi A; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Le Anh TN; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • McTaggart S; Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
  • Abbasizanjani H; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK.
  • Hollings S; Public Health Scotland, Edinburgh, UK.
  • Scourfield A; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, UK.
  • Lyons RA; NHS Digital, London, UK.
  • Griffiths R; UCLH NHS Foundation Trust, London, UK.
  • Lyons J; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, UK.
  • Davies G; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, UK.
  • Harris D; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, UK.
  • Handy A; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, UK.
  • Mizani MA; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, UK.
  • Tomlinson C; Institute of Health Informatics, University College London, London, UK.
  • Thygesen JH; Institute of Health Informatics, University College London, London, UK.
  • Ashworth M; British Heart Foundation Data Science Centre, Health Data Research UK, London, UK.
  • Denaxas S; Institute of Health Informatics, University College London, London, UK.
  • Banerjee A; Institute of Health Informatics, University College London, London, UK.
  • Sterne JAC; King's College London, London, UK.
  • Brown P; Institute of Health Informatics, University College London, London, UK.
  • Bullard I; British Heart Foundation Data Science Centre, Health Data Research UK, London, UK.
  • Priedon R; Health Data Research UK, London, UK.
  • Mamas MA; BHF Accelerator, University College London, London, UK.
  • Slee A; Institute of Health Informatics, University College London, London, UK.
  • Lorgelly P; Department of Cardiology, Barts Health NHS Trust, London, UK.
  • Pirmohamed M; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Khunti K; NIHR Bristol Biomedical Research Centre, Bristol, UK.
  • Morris AD; Health Data Research UK South-West, Bristol, UK.
  • Sudlow C; NHS Digital, London, UK.
  • Akbari A; NHS Digital, London, UK.
  • Bennie M; British Heart Foundation Data Science Centre, Health Data Research UK, London, UK.
  • Sattar N; Keele University, Keele, UK.
  • Sofat R; NHSX, London, UK.
Nat Med ; 29(1): 219-225, 2023 01.
Article em En | MEDLINE | ID: mdl-36658423
How the Coronavirus Disease 2019 (COVID-19) pandemic has affected prevention and management of cardiovascular disease (CVD) is not fully understood. In this study, we used medication data as a proxy for CVD management using routinely collected, de-identified, individual-level data comprising 1.32 billion records of community-dispensed CVD medications from England, Scotland and Wales between April 2018 and July 2021. Here we describe monthly counts of prevalent and incident medications dispensed, as well as percentage changes compared to the previous year, for several CVD-related indications, focusing on hypertension, hypercholesterolemia and diabetes. We observed a decline in the dispensing of antihypertensive medications between March 2020 and July 2021, with 491,306 fewer individuals initiating treatment than expected. This decline was predicted to result in 13,662 additional CVD events, including 2,281 cases of myocardial infarction and 3,474 cases of stroke, should individuals remain untreated over their lifecourse. Incident use of lipid-lowering medications decreased by 16,744 patients per month during the first half of 2021 as compared to 2019. By contrast, incident use of medications to treat type 2 diabetes mellitus, other than insulin, increased by approximately 623 patients per month for the same time period. In light of these results, methods to identify and treat individuals who have missed treatment for CVD risk factors and remain undiagnosed are urgently required to avoid large numbers of excess future CVD events, an indirect impact of the COVID-19 pandemic.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / COVID-19 / Hipertensão Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / COVID-19 / Hipertensão Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article